SLDB Solid Biosciences, Inc.

4.11-0.15 (-3.52%)
Close: December 13, 2019

Quote

Previous Close
$4.11
Day Range
$4.08-$4.44
52 Week Range
$2.75-$32.85
Volume
600,609
Avg Volume
1,283,126
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$189.01M
Enterprise Value (EV)
$74.48M
PE Ratio
-
EV/EBITDA
-1.00
Price/Sales
-
Price/Book
1.51
PEG Ratio
0.07

Financials

Revenue
-
Gross Profit
-$1.57M
EBITDA
-$74.12M
EPS, ttm
-$2.90
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
3/26/2020 (103 days)
Debt to Equity
1%
Debt
$7.93M
Cash
$122.46M
Net Debt
-

Performance

Beta
1.24
200 Day Moving Avg
$7.84
50 Day Moving Avg
$7.86
52 Week Change
-82.47%
YTD Change
-89.31%
1 Month Change
30.06%
3 Month Change
-60.86%
6 Month Change
-17.64%
1 Year Change
-82.47%
2 Year Change
-73.38%
5 Year Change
-73.38%

Share Count

Shares Outstanding
46.0M
Float
30.3M
Restricted Shares
15.7M
Restricted Shares, %
34.14%

Solid Biosciences, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Ilan Ganot

Website: http://www.solidbio.com

Description: Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Employees: 111